TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC BioPharm (NASDAQ: TCBP) has outlined its 2023 strategic plan, focusing on the development of its lead product, TCB-008, an allogeneic gamma-delta T cell therapy for cancer. The Company aims to pursue exclusive partnerships for clinical research, enhancing its competitive edge in the evolving cell therapy landscape. TCB-008 is set for FDA IND filing in Q3 2023 for Acute Myeloid Leukemia and will expand into CAR therapy targeting ovarian cancer. With over 313,000 new ovarian cancer cases reported in 2020, the Company is aligning its assets for better market positioning. TCBP is focused on establishing collaborations and increasing its intellectual property portfolio, aiming for a pivotal role in gamma-delta T cell therapies. The CEO emphasized the importance of partnerships and efficient capital management for long-term growth.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company, is set to participate in the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. This summit offers unique tax advantages for attendees, aimed at enhancing their investment strategies. Keynote panels and training sessions will be led by industry experts, covering the latest trends and best practices.

On April 26, at 11:00 am ET, TC BioPharm management will present on Track 2. The company's focus is on developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials targeting acute myeloid leukemia. TC BioPharm is recognized for its allogeneic approach and maintains a robust patent portfolio in this innovative field.

The report titled "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" highlights the emerging potential of CD276 immune checkpoint inhibitors in cancer treatment. It forecasts a market value exceeding US$ 1 Billion by 2028, with initial sales of approved therapies projected between US$ 100 Million and US$ 150 Million within their first year. Currently, over 30 drugs are in clinical trials targeting CD276, with various pharmaceutical companies, including Daiichi Sankyo, pursuing innovative treatments. Though no FDA-approved CD276 therapies exist, promising early results from clinical studies indicate significant market opportunities ahead.

TC BioPharm (NASDAQ: TCBP) announced the closure of a public offering, issuing 3,437,500 American Depositary Shares (ADSs), priced at $1.60 each, raising approximately $5.5 million. This includes Series C warrants exercisable at $1.75 per ADS. The funding is intended to extend the company's cash runway through the US FDA IND filing. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering, filed with the SEC on March 27, 2023. TC BioPharm specializes in gamma-delta T cell therapies for cancer, leading pivotal clinical studies in oncology.

TC BioPharm (NASDAQ: TCBP) announced the pricing of a public offering of 3,437,500 American Depositary Shares (ADSs) at $1.60 each, aiming to raise $5.5 million before expenses. The offering, expected to close on or about March 30, 2023, includes Series C warrants with an exercise price of $1.75 per ADS. Proceeds will support working capital and corporate purposes. Additionally, existing warrants for 2,800,000 ADSs issued in November 2022 will be amended to reduce exercise price to $1.75 upon closing. The registration statement was effective as of March 27, 2023.

TC BioPharm (NASDAQ: TCBP) has announced a corporate restructuring aimed at reducing overhead and extending its cash runway. The company plans to cut its workforce by up to 30%, with an expected annual cost saving of over $3 million. This restructuring aligns with TC BioPharm's strategic focus on advancing its lead therapeutic program, TCB-008, and other clinical trials. The CEO emphasized the necessity of these changes to ensure the company's long-term sustainability amid challenging market conditions. The company is also exploring non-dilutive funding options and strategic partnerships to bolster its operations.